XERS Historical PE Ratio Notes

— Xeris Biopharma Holdings (XERS) is a specialty pharmaceutical company that develops & commercializes innovative therapies for endocrine & neurology conditions, primarily focusing on ready-to-use injectable and infusible drug formulations. Its core products include Gvoke—a premixed, ready-to-inject glucagon for severe hypoglycemia—and Keveyis, used to treat primary periodic paralysis. The company's unique formulation technologies aim to improve patient convenience & reduce risks associated with traditional drug preparations. Historically, XERS has invested heavily in R&D and commercial infrastructure, which impacts their earnings profile; as a result, you may notice periods of negative or minimal earnings per share (EPS) in your historical analysis. This can lead to very high or undefined price-to-earnings (PE) ratios in certain years, particularly when net losses are reported. The market has tended to value XERS based more on anticipated future revenues & the disruptive potential of its drug pipeline, rather than consistent profitability. As you review historical PE ratios and related data, it’s essential to recognize that XERS’s PE ratio may not always reflect traditional company maturity, but rather investor expectations about future growth & the eventual path to profitability.

On this page we presented the XERS Historical PE Ratio information for Xeris Biopharma Holdings' stock. The average XERS historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 95.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average XERS historical PE based on this TTM earnings result method is 110.5. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this XERS historical PE result, against the recent PE: when this page was posted on 6/5/2026, the most recent closing price for XERS had been 6.18, and the most recent quarterly earnings result, annualized, was 0.04. Meanwhile, the most recent TTM earnings summed to 0.06. From these numbers, we calculate the recent XERS PE on 6/5/2026 based on annualized quarterly EPS was 154.5. Based on XERS's history, that recent PE is elevated relative to the historical average, with the recent PE 61.8% higher than the historical average PE across our data set for Xeris Biopharma Holdings. Looking at the recent XERS PE on 6/5/2026 based on TTM EPS, we calculate the ratio at 103.0. Based on XERS's history, that recent PE is low relative to the historical average, with the recent PE 6.8% lower than the average PE across our Xeris Biopharma Holdings data set with TTM EPS used in the calculation at each period.

Another interesting XERS historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for XERS, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for XERS, we start with the past four EPS numbers and we first sort them from lowest to highest: -0.01, 0.00, 0.01, and 0.06. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.00 and 0.01 — which gives us the median of 0.01. Basically the way to think about this 0.01 number is this: for the trailing four earnings reports, 0.01 marks the "middle ground" number where XERS has reported a value higher than 0.01 half the time, and has reported a value lower than 0.01 half the time. Annualizing that median value then gets us to 0.04/share, which we use as the denominator in our next PE calculation. With 6.18 as the numerator (as of 6/5/2026), the calculation is then 6.18 / 0.04 = 154.5 as the XERS PE ratio as of 6/5/2026, based on that annualized median value we calculated.

For self directed investors doing their due diligence on XERS or any other given stock, valuation analysis for XERS can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Xeris Biopharma Holdings PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for XERS. Thanks for visiting, and the next time you need to research XERS Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.